No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
KNSA240719C17500
- 1.99
- +0.28+16.37%
15min DelayClose Jul 3 12:59 ET
1.99High1.99Low
1.99Open1.71Pre Close1 Volume33 Open Interest17.50Strike Price199.00Turnover128.32%IV2.04%PremiumJul 19, 2024Expiry Date1.60Intrinsic Value100Multiplier15DDays to Expiry0.39Extrinsic Value100Contract SizeAmericanOptions Type0.6823Delta0.0716Gamma6.76Leverage Ratio-0.0613Theta0.0042Rho4.61Eff Leverage0.0138Vega
Intraday
- 5D
- Daily
News
Kiniksa Pharmaceuticals Files $400 Million Mixed Shelf
Kiniksa Pharmaceuticals (KNSA) on Friday filed a registration statement for the potential offering of up to $400 million worth of securities from time to time. The filing covers the potential sale of
Express News | Kiniksa Pharmaceuticals Ltd Files for Mixed Shelf of up to $400 Mln - SEC Filing
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday
Health care stocks were mixed pre-bell Wednesday, with the iShares Biotechnology ETF (IBB) down 0.1% and the Health Care Select Sector SPDR Fund (XLV) up 0.5% recently. Savara (SVRA) rose past 17% aft
Express News | Kiniksa Pharmaceuticals - Samsung to Perform Tech. Transfer, Process Performance Qualification, Manufacturing & Supply Services for Supply of Arcalyst
Express News | Kiniksa Pharmaceuticals Ltd - Unit Entered Master Services Agreement and Product Specific Agreement With Samsung Biologics Co., Ltd.
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Comments
The share price rise is a fair reaction to the company's revenue growth. More gains could follow if the trend continues. Yet, consider the company's profitability and cash flow before investing.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Delivers Shareholders Respectable 66% Return Over 1 Year, Surging 4.7% in the Last Week AloneKiniksa Pharmaceuticals' low P/S ratio may be due to its forecast growth being lower than the industry. Shareholders accept this, conceding future revenue probably won't surprise positively. It's hard to see the share price rising strongly soon under these circumstances.
$Cellectar BioSciences(CLRB.US$ Phase 2
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2 ...
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2 ...
37
6
Kiniksa Pharmaceuticals' growing cash burn is offset by substantial cash reserves & signs of business growth. The firm can issue shares or borrow cheaply to fund further growth.
Read more